MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Predictors of Death within 6 Months in Individuals with Dementia with Lewy Bodies

    M. Armstrong, Y. Dai, B. Labarre, H. Fechtel, K. Sovich, J. Galvin, H. Paulson, S. Maixner, C. Manning, J. Fields, A. Lunde, B. Boeve, L. Forsberg, A. Taylor, Z. Li (Gainesville, USA)

    Objective: To assess predictors of death in the subsequent 6 months in dementia with Lewy bodies (DLB). Background: Individuals with DLB commonly die of disease-related…
  • 2024 International Congress

    Unmet Motor and Nonmotor Needs of People with Parkinson’s in the Final Year of Life

    K. Rukavina, M. Al-Agil, K. Poplawska-Domaszewicz, S. Veronese, D. Oliver, K. Ray Chaudhuri (London, United Kingdom)

    Objective: To assess main issues People with Parkinson’s (PD, PwP) wished to discuss at clinical consultations with movement disorders specialists during the final year of…
  • 2024 International Congress

    Noradrenaline treatment of apathy and impulsivity in participants with Progressive Supranuclear Palsy syndromes (NORAPS). A Phase II clinical trial – ISRCTN99462035.

    R. Durcan, J. Rowe (Cambridge, United Kingdom)

    Objective: The NORAPS Phase II clinical trial seeks to demonstrate safety, tolerability and efficacy of atomoxetine in Progressive Supranuclear Palsy (PSP). Background: PSP is a…
  • 2024 International Congress

    Personality may influence the response to apomorphine infusion in Parkinson’s disease patients

    M. Boussac, E. Harroch, C. Barthelemy, F. Ory-Magne, C. Leung, M. Fabbri, C. Arbus, C. Brefel-Courbon (Toulouse, France)

    Objective: to evaluate the impact of personality on quality-of-life (QoL) amelioration after treatment by Continuous Subcutaneous Apomorphine Infusion (CSAI) in Parkinson’s disease (PD). Background: PD…
  • 2024 International Congress

    A Phase 2 Randomized Clinical Trial of TAK-071, an Acetylcholine M1 Receptor Positive Allosteric Modulator, in Parkinson Disease with Cognitive Impairment

    N. Shanbhag, J. Padmanabhan, Z. Zhang, B. Harel, H. Jia, T. Kangarloo, W. Yin, A. Dowling, A. Laurenza, P. Khudyakov, K. Galinksy, R. Latzman, T. Simuni, D. Weintraub, F. Horak, C. Lustig, P. Maruff, A. Simen (Cambridge, USA)

    Objective: To study the safety and efficacy of TAK-071, an M1 positive allosteric modulator, in adults with Parkinson disease (PD) with increased risk for falls…
  • 2024 International Congress

    Impact of IPX203 on Parkinson’s patients’ motor states upon awakening: analysis of patient diary data

    S. Isaacson, H. Fernandez, C. Kilbane, G. Banisadr, A. Pitman, S. Fisher, R. D'Souza (Boca Raton, USA)

    Objective: To evaluate “On” upon awakening in Parkinson’s disease patients taking IPX203 in the RISE-PD phase 3 clinical trial. Background: IPX203 is a novel extended-release,…
  • 2024 International Congress

    The HIIT-Home4Parkinson’s study

    C. Harpham, L. Connolly, H. Gunn, J. Marsden (Plymouth, United Kingdom)

    Objective: This study aims to evaluate the practicality and utility of a novel, co-created home-based high-intensity interval training (HIIT) programme for people with Parkinson’s (PwP).…
  • 2024 International Congress

    Interim results of a mixed method research-in-action study to evaluate and improve patient and public involvement within the EJS ACT-PD initiative

    M-L. Zeissler, N. Lapelle, S. Collins, E. Cowd, C. Gonzalez-Robles, R. Ellis-Doyle, G. Mills, R. Petty, T. Foltynie, C. Carroll, K. Mcfarthing (Plymouth, United Kingdom)

    Objective: To improve patient and public involvement and engagement (PPIE) within EJS ACT-PD by evaluating members’ perceptions of PPIE through a mixed methods research-in-action study.…
  • 2024 International Congress

    Predictability of Motor States With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease

    R. Hauser, M. Bouchard, D. Santos-Garcia, L. Bergmann, R. Gupta, L. Harmer, M. Shah, C. Yan, S. Isaacson (Tampa, USA)

    Objective: To assess predictability of “On” or “Off” motor states in patients (pts) with advanced Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDp/CDp). Background: Pts with…
  • 2024 International Congress

    Patient Experiences Initiating Continuous Subcutaneous Apomorphine Infusion (CSAI): An Interview-Based Survey of InfusON Study Participants

    P. Agarwal, N. Crouse, A. Breiteneicher, M. Formella (Kirkland, USA)

    Objective: Obtain patient feedback on experiences initiating and using continuous subcutaneous apomorphine infusion (CSAI). Background: Previously reported data from the ongoing InfusON study demonstrated that…
  • « Previous Page
  • 1
  • …
  • 129
  • 130
  • 131
  • 132
  • 133
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Life expectancy with and without Parkinson’s disease in the general population
    • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
    • An atypical and interesting feature of Parkinson´s disease
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley